Quizartinib HCl

Quizartinib (AC220) is a potent and selective oral inhibitor of class III receptor tyrosine kinases, primarily targeting FLT3. It is a key research tool for studying FLT3-ITD mutant acute myeloid leukemia (AML), demonstrating efficacy in both cellular assays and in vivo models to investigate proliferation and apoptosis mechanisms.